Antigen-specific antibody responses in lupus patients following immunization

Arthritis and Rheumatism

Volumn 41, Issue 10, 1998, Pages 1828-1834

  Battafarano, Daniel F ^a,c   Battafarano, Nicholas J ^a   Larsen, Lawrence ^a   Dyer, P Dennis ^a   Older, Steven A ^b   Muehlbauer, S ^a   Hoyt, A ^a   Lima, J ^a   Goodman, David ^a   Lieberman, Michael ^a   Enzenauer, Raymond J ^a  

^a FITZSIMONS ARMY MEDICAL CENTER   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

^c US Army Medical Department Center & School   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; PREDNISONE; TETANUS TOXOID;

ADULT; AGED; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL INFECTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; ANTIBODY FORMATION; AZATHIOPRINE; BACTERIAL VACCINES; CYCLOPHOSPHAMIDE; EPITOPES; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PREDNISONE; STREPTOCOCCUS PNEUMONIAE; TETANUS TOXOID;

EID: 0031719107     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199810)41:10<1828::AID-ART15>3.0.CO;2-T     Document Type: Article

References (46)

1. Staples PJ, Gerding DN, Decker JL, Gordon RS Jr. Incidence of infection in systemic lupus erythematosus. Arthritis Rheum 1974; 17:1-10.
2. Steinberg AD. Management of systemic lupus erythematosus. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, editors. Textbook of rheumatology. 2nd ed. Philadelphia: WB Saunders; 1985. p. 1098-115.
3. Steinberg AD. Management of systemic lupus erythematosus. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, editors. Textbook of rheumatology. 3rd ed. Philadelphia: WB Saunders; 1989. p. 1130-46.
4. Williams GW, Steinberg AD, Reinertsen JL, Klassen LW, Decker JL, Dolin R. Influenza immunization in systemic lupus erythematosus: a double-blind trial. Ann Intern Med 1978;88:729-34.
5. Klippel JH, Karsh J, Stahl NI, Decker JL, Steinberg AD, Schiffman G. A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus. Arthritis Rheum 1979;22: 1321-5.
6. Tudela P, Marti S, Bonal J. Systemic lupus erythematosus and vaccination against hepatitis B [letter]. Nephron 1992;62:236.
7. Ayvazian LF, Badger TL. Disseminated lupus erythematosus occurring among student nurses. N Engl J Med 1948;239:565-70.
8. Turner-Stokes L, Cambridge G, Corcoran T, Oxford JS, Snaith ML. In vitro response to influenza immunisation by peripheral blood mononuclear cells from patients with systemic lupus erythematosus and other autoimmune diseases. Ann Rheum Dis 1988;47:532-5.
9. Klippel JH. Systemic lupus erythematosus management. In: Klippel JH, Dieppe PA, editors. Rheumatology. London: Mosby; 1994. p. 6.6.1-6.6.8.
10. Wallace DJ. Other medications and adjunctive measures. In: Wallace DE, Hahn BH, editors. Dubois' lupus erythematosus. 4th ed. Philadelphia: Lea & Febiger; 1993. p. 600-5.
11. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
12. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
13. Urowitz MB, Gladman DD, Tozman EC, Goldsmith CH. The lupus activity criteria count (LACC). J Rheumatol 1984;11:783-7.
14. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus: a prospective cohort study. Arthritis Rheum 1991;34:937-44.
15. Fox RA. Disseminated lupus erythematosus - an allergic disease? Arch Pathol 1943;36:311-5.
16. Ambrosino DM, Siber GR. Simultaneous administration of vaccines for Haemophilus influenzae type b, pneumococci, and meningococci. J Infect Dis 1986;154:893-6.
17. Rothstein EP, Bernstein HH, Glode MP, Laussucq S, Nonenmacher J, Long SS, et al. Simultaneous administration of a diphtheria and tetanus toxoids and acellular pertussis vaccine with measles-mumps-rubella and oral poliovirus vaccines. Am J Dis Child 1993;147:854-7.
18. Rose DN, Schechter CB, Sacks HS. Influenza and pneumococcal vaccination of HIV-infected patients: a policy analysis. Am J Med 1993;94:160-8.
19. Schattner A, Ben-Chetrit E, Schmilovitz H. Poliovaccines and the course of systemic lupus erythematosus - a retrospective study of 73 patients. Vaccine 1992;10:98-100.
20. Louie JS, Nies KM, Shoji KT, Fraback RC, Ahrass C, Border W, et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med 1978;88:790-2.
21. Brodman R, Gilfillan R, Glass D, Schur PH. Influenza vaccine response in systemic lupus erythematosus. Ann Intern Med 1978; 88:735-40.
22. Ristow SC, Douglas RG, Condemi JJ. Influenza vaccination of patients with systemic lupus erythematosus. Ann Intern Med 1978;88:786-9.
23. Gartner S, Emlen W. Hepatitis B vaccination of SLE patients [abstract]. Arthritis Rheum 1996;39 Suppl 9:S291.
24. Abe T, Homma M. Immunological reactivity in patients with systemic lupus erythematosus. Acta Rheumatol Scand 1971;17:35-46.
25. Pabico RC, Douglas RG, Betts RF, McKenna BA, Freeman RB. Influenza vaccination of patients with glomerular diseases: effects on creatinine clearance, urinary protein excretion, and antibody response. Ann Intern Med 1974;81:171-7.
26. Croft SM, Schiffman G, Snyder E, Herrmann K, James K, Jarrett MP. Specific antibody response after in vivo antigenic stimulation in systemic lupus erythematosus. J Rheumatol 1984;11:141-6.
27. O'Dell J, Gilg J, Palmer W, Haire C, Klassen L, Moore G. Pneumococcal vaccination: decreased antibody response in rheumatoid arthritis patients on methotrexate [abstract]. Arthritis Rheum 1992;35 Suppl 9:S197.
28. Baum J, Ziff M. Decreased 19S antibody response to bacterial antigens in systemic lupus erythematosus. J Clin Invest 1969;48: 758-67.
29. Meiselas LE, Zingale SB, Lee SL, Richman S, Siegel M. Antibody production in rheumatic diseases: the effect of brucella antigen. J Clin Invest 1961;40:1872-81.
30. Zingale SB, Sánchez Avalos JC, Andrada JA, Stringa SG, Manni JA. Appearance of anticoagulant factors and certain "autoimmune" antibodies following antigenic stimulation with blood group substances in patients with systemic lupus erythematosus. Arthritis Rheum 1963;6:581-98.
31. Baum J. Hyporeactivity to an exogenous antigen in systemic lupus erythematosus [abstract]. Arthritis Rheum 1967;10:265-6.
32. Ruben FL, Nagel J, Fireman P. Antitoxin responses in the elderly to tetanus-diphtheria (TD) immunization. Am J Epidemiol 1978; 108:145-9.
33. Murphy NM, Olney DB, Brakenbury PH. Objective verification of tetanus immune status in an apparently non-immune population. Br J Clin Pract 1994;48:8-9.
34. D'Angio CT, Maniscalco WM, Pichichero ME. Immunologic response of extremely premature infants to tetanus. Haemophilus influenzae, and polio immunizations. Pediatrics 1995;96:18-22.
35. Jarrett MP, Schiffman G, Barland P, Grayzel AI. Impaired response to pneumococcal vaccine in systemic lupus erythematosus. Arthritis Rheum 1980;23:1287-93.
36. Myers MG, Beckman CW, Vosdingh RA, Hankins WA. Primary immunization with tetanus and diphtheria toxoids: reaction rates and immunogenicity in older children and adults. JAMA 1982;248: 2478-80.
37. Margolis KL, Nichol KL, Poland GA, Pluhar RE. Frequency of adverse reactions to influenza vaccine in the elderly: a randomized placebo-controlled trial. JAMA 1990;264:1139-41.
38. Mullooly JP, Bennett MD, Hornbrook MC, Barker WH, Williams WW, Patriarca PA, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in an health maintenance organization. Ann Intern Med 1994;121:947-52.
39. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453-60.
40. Pneumococcal polysaccharide vaccine. MMWR Morb Mortal Wkly Rep 1978;27:25-31.
41. Piliero P, Furie R. Functional asplenia in systemic lupus erythematosus. Semin Arthritis Rheum 1980;20:185-9.
42. Childs JC, Adelizzi RA, Dabrow MB, Freed N. Splenic hypofunction in systemic lupus erythematosus. J Am Osteopath Assoc 1994;94:414-5.
43. Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk for serious pneumococcal infections. Ann Intern Med 1984;101:325-30.
44. Simberkoff MS, Cross AP, Al-Ibrahim M, Baltch AL, Geiseler PJ, Nadler J, et al. Efficacy of pneumococcal vaccine in high risk patients: results of a Veterans Administration cooperative study. N Engl J Med 1986;315:1318-27.
45. McDonald E, Jarrett MP, Schiffman G, Grayzel AI. Persistence of pneumococcal antibodies after immunization in patients with systemic lupus erythematosus. J Rheumatol 1984;11:306-8.
46. Immunizations Practices Advisory Committee. General recommendations on immunization: guidelines from the Immunization Practices Advisory Committee, Centers for Disease Control. Ann Intern Med 1989;111:133-42.